Kymera Therapeutics stock reports 465.2 percent revenue growth

Published on 10/01/2026 at 00:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kymera Therapeutics stock posted USD 65.0 million in Q2 2026 revenue, up 465.2 percent year over year. Stifel raised its target to USD 152.00 on September 22, 2026.

KYMR, US50153V1061, Illustration mit AI erstellt.

Kymera Therapeutics (ISIN US50153V1061) generated USD 65.0 million in Q2 2026 revenue, up 465.2 percent from the prior-year quarter, according to MarketBeat on September 22, 2026. The result puts collaboration income at the center of the investment case while Kymera remains a clinical-stage biotech company.

Q2 revenue reaches USD 65.0 million

The company reported an adjusted loss of USD 0.62 per share for Q2 2026, beating the USD 0.71 consensus loss by USD 0.09, according to MarketBeat. Revenue also exceeded the USD 32.78 million consensus estimate, creating a USD 32.22 million gap between reported and expected sales.

The 465.2 percent annual increase is eye-catching, but its composition matters. The latest quarterly revenue reflects collaboration payments rather than recurring product sales, so milestone timing remains important when investors assess the durability of the top-line comparison.

Stifel target rises to USD 152.00

Stifel Nicolaus raised its Kymera price target to USD 152.00 from USD 132.00 and maintained a Buy rating in a research note dated September 22, 2026, as MarketBeat reported. The USD 20.00 increase in the target is a sharper signal than the broader consensus alone because it reflects a named analyst action.

MarketBeat also cited an average target of USD 133.21 and a Moderate Buy consensus from 25 analysts on September 22, 2026. That target remains below Stifel's USD 152.00 objective, showing that the analyst range is broad even after the latest revision.

Targeted degradation drives the pipeline

Kymera's investor-relations page describes a platform built around targeted protein degradation and oral medicines for chronic inflammatory diseases. Its latest-quarter section identifies Q2 2026 as the current reporting period, while the pipeline spans immunology and oncology programs.

The financial profile therefore combines a USD 65.0 million quarterly revenue base with a USD 0.62 adjusted per-share loss. For investors, the key distinction is whether future collaboration milestones can be converted into a broader and more repeatable commercial revenue stream.